000 01525 a2200433 4500
005 20250518050531.0
264 0 _c20200731
008 202007s 0 0 eng d
022 _a1756-8722
024 7 _a10.1186/s13045-019-0761-2
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aLi, Weiping
245 0 0 _aTargeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors.
_h[electronic resource]
260 _bJournal of hematology & oncology
_c07 2019
300 _a73 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650 0 4 _aCell Line, Tumor
650 0 4 _aCell Proliferation
650 0 4 _aCell Survival
650 0 4 _aFemale
650 0 4 _aHumans
650 0 4 _aLymphoma, Large B-Cell, Diffuse
_xgenetics
650 0 4 _aMale
650 0 4 _aProto-Oncogene Proteins c-bcl-2
_xmetabolism
650 0 4 _aProto-Oncogene Proteins c-bcl-6
_xmetabolism
650 0 4 _aProto-Oncogene Proteins c-myc
_xmetabolism
650 0 4 _aTransfection
700 1 _aGupta, Shiv K
700 1 _aHan, Weiguo
700 1 _aKundson, Ryan A
700 1 _aNelson, Sara
700 1 _aKnutson, Darlene
700 1 _aGreipp, Patricia T
700 1 _aElsawa, Sherine F
700 1 _aSotomayor, Eduardo M
700 1 _aGupta, Mamta
773 0 _tJournal of hematology & oncology
_gvol. 12
_gno. 1
_gp. 73
856 4 0 _uhttps://doi.org/10.1186/s13045-019-0761-2
_zAvailable from publisher's website
999 _c29884706
_d29884706